Yesterday I started digging in to Matt McCall’s tease about a huge opportunity in Chinese biotech… and, as promised, today I’m finishing the job. The basic premise is that China is pushing to make biopharma a bigger part of its economy in both the current five-year plan and the “made in China 2025” plan, and […]
Articles
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
The second biotech appears to be Ascletis Pharma (1672.HK) which was the first biotech to list on the HK exchange under ...